NASDAQ:PRVL Prevail Therapeutics (PRVL) Stock Price, News & Analysis → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free PRVL Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$23.00▼$23.0050-Day Range$22.91▼$23.2052-Week Range$9.02▼$23.35VolumeN/AAverage Volume955,800 shsMarket Capitalization$787.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Prevail Therapeutics alerts: Email Address Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. About Prevail Therapeutics Stock (NASDAQ:PRVL)Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.Read More Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. PRVL Stock News HeadlinesApril 16, 2024 | tmcnet.comPrecision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail TherapeuticsApril 16, 2024 | marketwatch.comPrecision BioSciences to Regain Programs After Prevail Team-Up EndsApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. April 2, 2024 | yahoo.comNew England Metal & Hardcore Fest 2024 Lineup: Killswitch Engage and Slaughter to PrevailMarch 6, 2024 | msn.comHalestorm Announce Co-Headlining Tour in 2024 with I PrevailMarch 4, 2024 | msn.comHalestorm + I Prevail Announce 2024 North American Summer TourFebruary 5, 2024 | uk.movies.yahoo.comLori Kay Relaunches Management & Production Company Prevail Artist EntertainmentNovember 2, 2023 | yahoo.comPrimates Prevail in Teaser for Kingdom of the Planet of the Apes: WatchApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. October 28, 2023 | ft.comHumanity must prevail in GazaOctober 24, 2023 | msn.comInsane Airflow, Impressively Durable: Specialized S-Works Prevail 3 Bike Helmet 1-Year ReviewOctober 12, 2023 | msn.comPrevail Bank in Wausau helping community growSeptember 18, 2023 | finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLCJuly 25, 2023 | msn.comSpecialized/Fjallraven Prevail Helmet review: summery lid for bikepackingJuly 18, 2023 | msn.comHard rock band Godsmack, with I Prevail, will play the Resch Center in SeptemberMay 19, 2023 | benzinga.comBriaCell Closes $4 Million Strategic Investment by Prevail Partners, LLC at US$8.63 per ShareMay 9, 2023 | usnews.comNorth Korea's Kim Says Russia 'Will Prevail' Over Hostile ForcesMarch 26, 2023 | abcnews.go.comAbortion-rights supporters prevail in New Hampshire HouseFebruary 1, 2023 | msn.comNovartis Ag (NVS) Q4 2022 Earnings Call TranscriptJanuary 5, 2023 | forbes.comWhy Some Teams Fail And Others PrevailJanuary 5, 2023 | msn.comDelhi Wakes Up To Chilling 3 Degrees, Season’s Lowest; Coldwave, Fog To Prevail In These States | Full ForecastNovember 21, 2022 | msn.comPrevail Bank makes donation to local teen homeless shelterNovember 2, 2022 | seekingalpha.comVanda Pharmaceuticals Inc. (VNDA) Q3 2022 Earnings Call TranscriptNovember 1, 2022 | msn.comPrevail Bank Eau Claire branch grand reopeningSeptember 24, 2022 | news.yahoo.com5 things to know from I Prevail's 'True Power' Tour stop in LubbockSeptember 9, 2022 | yahoo.comI Prevail Reflect on the Pandemic, ‘Trauma’ and New LP ‘True Power’August 4, 2022 | msn.comPrevail Bank donates funds for school supply driveSee More Headlines Receive PRVL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prevail Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2020Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PRVL CUSIPN/A CIKN/A Webwww.prevailtherapeutics.com Phone917-336-9310FaxN/AEmployees66Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-55.57% Return on Assets-48.14% Debt Debt-to-Equity RatioN/A Current Ratio7.56 Quick Ratio7.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.85 per share Price / Book4.74Miscellaneous Outstanding Shares34,246,000Free FloatN/AMarket Cap$787.66 million OptionableNot Optionable Beta1.59 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Asa Abeliovich M.D. (Age 56)Ph.D., Founder, Pres, CEO & Director Comp: $737.47kDr. Yong Dai Ph.D. (Age 49)Chief Technology Officer Comp: $450.62kDr. Jeffrey Sevigny M.D. (Age 51)Chief Medical Officer Comp: $593kDr. Brett Kaplan M.D. (Age 46)CFO & Sec. Ms. Kira M. SchwartzGen. CounselMs. Emily Minkow (Age 37)Chief Bus. Officer Dr. Franz F. Hefti Ph.D. (Age 72)Chief Devel. Officer More ExecutivesKey CompetitorsREGENXBIONASDAQ:RGNXRelay TherapeuticsNASDAQ:RLAYCARGO TherapeuticsNASDAQ:CRGXKyverna TherapeuticsNASDAQ:KYTXCullinan OncologyNASDAQ:CGEMView All Competitors PRVL Stock Analysis - Frequently Asked Questions How were Prevail Therapeutics' earnings last quarter? Prevail Therapeutics Inc. (NASDAQ:PRVL) announced its earnings results on Friday, November, 13th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.64) by $0.09. What other stocks do shareholders of Prevail Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prevail Therapeutics investors own include Sorrento Therapeutics (SRNE), Alector (ALEC), Gossamer Bio (GOSS), Editas Medicine (EDIT), Harpoon Therapeutics (HARP), Atreca (BCEL), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), Inovio Pharmaceuticals (INO) and Stoke Therapeutics (STOK). When did Prevail Therapeutics IPO? Prevail Therapeutics (PRVL) raised $126 million in an initial public offering on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. This page (NASDAQ:PRVL) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJim Cramer’s “The Biggest Drug Ever”Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prevail Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
